Cutaneous leishmaniasis is endemic in the tropics and neotropics. It is often referred to as a group of diseases because of the varied spectrum of clinical manifestations, which range from small cutaneous nodules to gross mucosal tissue destruction. Cutaneous leishmaniasis can be caused by several Leishmania spp and is transmitted to human beings and animals by sandfl ies. Despite its increasing worldwide incidence, but because it is rarely fatal, cutaneous leishmaniasis has become one of the so-called neglected diseases, with little interest by fi nancial donors, public-health authorities, and professionals to implement activities to research, prevent, or control the disease. In endemic countries, diagnosis is often made clinically and, if possible, by microscopic examination of lesion biopsy smears to visually confi rm leishmania parasites as the cause. The use of more sophisticated diagnostic techniques that allow for species identifi cation is usually restricted to research or clinical settings in non-endemic countries. The mainstays of cutaneous leishmaniasis treatment are pentavalent antimonials, with new oral and topical treatment alternatives only becoming available within the past few years; a vaccine currently does not exist. Disease prevention and control are diffi cult because of the complexity of cutaneous leishmaniasis epizoology, and the few options available for eff ective vector control.
Introduction
Leishmania parasites are the causal agents of leishmaniasis, a group of protozoan diseases transmitted to mammals, including human beings, by phlebotomine sandfl ies. Globally, there are an estimated 1·5-2 million new cases and 70 000 deaths each year, and 350 million people are at risk of infection and disease. 1 Morbidity and mortality because of the leishmaniases cause an estimated 2·4 million disability-adjusted life-years. 1 The leishmaniases are characterised by a spectrum of clinical manifestations: ulcerative skin lesions developing at the site of the sandfl y bite (localised cutaneous leishmaniasis [LCL] ); multiple non-ulcerative nodules (diff use cutaneous leishmaniasis [DCL] ); destructive mucosal infl ammation (mucosal leishmaniasis); and disseminated visceral infection (visceral leishmaniasis). The clinical spectrum observed in patients indicates the complexity of leishmaniasis epizoology: several Leishmania spp can cause disease (table 1) , and many sandfl y and mammalian species have been implicated as vectors and reservoir hosts, respectively.
We critically review the most recent data on the burden of the cutaneous leishmaniases, namely LCL, DCL, and mucosal leishmaniasis, their epidemiology, clinical pathology, diagnosis, treatment, prevention, and control. Visceral leishmaniasis has been reviewed elsewhere; [2] [3] [4] we did not review post kala-azar dermal leishmaniasis, because this is a manifestation seen in patients with visceral leishmaniasis after apparent clinical cure. 14 the global burden of cutaneous leishmaniasis is likely to be underestimated.
Main
Transmission cycles are adapting to peridomestic environments and are spreading to previously nonendemic areas as a result of urbanisation and deforestation, 15 with domestic animals as potential reservoirs. 7, 16 Additionally, economic hardship, 17 natural disasters, 18 armed confl ict, 19 and tourism 20 cause susceptible populations to migrate to areas endemic for cutaneous leishmaniasis, where exposure to infection results in noticeable epidemics. For example, whereas cutaneous leishmaniasis caused by Leishmania tropica was rare in Kabul, Afghanistan, before 1990, more than 25 000 mainly autochthonous cases were treated in 2003 (Reithinger R, unpublished data), with incidence estimated to be up to 67 500 new cases per year. 6 New foci of L tropica are also reported in Morocco, 21 Israel, 22 Syria, 10 Iran, 23 and Pakistan. 24 
Epidemiology
Several features characterise cutaneous leishmaniasis epidemiology. In established endemic areas, cutaneous leishmaniasis prevalence typically increases with age up to 15 years, after which prevalence levels off , presumably because of the acquisition of immunity. The infection can cluster within households, which is indicative of the short fl ight range of sandfl ies, 25 anthroponotic transmission, 6, 24 or genetic susceptibility. 26 Risk factors of disease commonly include sex (eg, sex bias usually points to behavioural patterns that increase vector exposure), age, household design and construction material, and presence of domestic animals. 6, 7, 15, 16, 27 Recent use of geographical information systems and remote sensing has allowed investigations of large-scale distributions and geographical risk factors of disease, but so far such research on cutaneous leishmaniasis has been scarce, 9, 28, 29 partly because of the complexity of the transmission cycle (fi gure 2). Better understanding of the relations between environmental factors and distributions of sandfl ies and infection in a wide range of transmission settings would contribute to current, largely anecdotal or laboratory-based, information on the importance of the environment to transmission (fi gure 2).
Sandfl ies and the epizoology of the cutaneous leishmaniases
Leishmania infections typically originate via the bite of sandfl ies belonging to either Phlebotomus spp (in Europe, North Africa, the middle east, and Asia; fi gure 3) or Lutzomyia spp (from southern USA to northern Argentina; fi gure 3). 25 Non-vector transmission (eg, by accidental laboratory infection) 30 is rare. Cutaneous leishmaniasis transmission is either anthroponotic or zoonotic, depending on whether human beings are the main reservoir host (table 1) .
Approximately 30 species or subspecies of sandfl ies are proven vectors, with more than 40 additional species probably involved in transmission. 25 Perhaps the most striking diff erence between so-called Old World large-scale cultivation of agricultural crops (eg, coff ee), 31 and marginal neighbourhoods of cities.
15
Sandfl ies will generally take blood from various hosts, and the loss of mammalian biodiversity as a result of deforestation, agricultural practices, and urbanisation can concentrate leishmania transmission by forcing vectors to feed on human beings and a progressively smaller number of synanthropic reservoirs (eg, domestication of Lutzomyia whitmani in Brazil). 32 Because mammals of several orders can be infected by the same Leishmania sp, it seems that more selective pressure is exerted on the parasite by the vector than the host. Natural leishmania infections are found in a range of non-human mammal hosts (mainly marsupials, rodents, edentates, and carnivores). So far, only a handful of reservoir hosts for the main Leishmania spp (ie, L infantum, L peruviana, L amazonensis, L mexicana, L guyanensis, L panamensis, L major, and L aethiopica) have been reported; 7, 33 the reservoir hosts of L braziliensis remain to be identifi ed conclusively. Reservoir implication is diffi cult because it is often specifi c to the local epizoological context and depends on many variables (eg, host abundance and distribution, infectiousness to the sandfl y vector), 34 which are rarely investigated.
Disease presentation and pathogenesis

Clinical symptoms
Several Leishmania spp can cause cutaneous leishmaniasis in human beings, although most infections probably remain symptomless. 2 The fi rst sign of an infection is typically a small erythema that develops after a variable prepatent period at the site where an infected sandfl y has bitten the host. The erythema develops into a papule, then a nodule that progressively ulcerates over a period of 2 weeks to 6 months to become the lesion that is characteristic of LCL. 35 Spontaneous healing usually results in lifelong protection from disease, which may or may not be restricted to the same Leishmania spp. Resolution of disease results in a lifelong cutaneous scar, which, depending on its size and location, may cause substantial trauma in aff ected individuals. 54 In DCL, which is seen rarely in parts of South and Central America, Ethiopia, and Kenya, parasite-laden, non-ulcerative nodules disseminate from the initial site of infection and may cover a patient's entire body. 35 Compared with LCL, DCL is diffi cult to treat and patients do not self-cure.
Although mucosal leishmaniasis can be caused by L panamensis, 55 L guyanensis, 56 L amazonensis, 57 L major,
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L tropica, 59 and L infantum, 60 it is most commonly associated with L braziliensis; 7, 61 thus, barring exceptions, [58] [59] [60] it is usually limited to South America. Mucosal involvement is the most serious complication in L braziliensis infections and can lead to disfi guring and life-threatening mucosal leishmaniasis (also known as espundia) in a varying proportion of patients. In most endemic areas, 1-10% of LCL infections result in mucosal leishmaniasis 1-5 years after LCL has healed, 7,61 but reports do exist for which mucosal leishmaniasis presented at the same time as LCL, 62 or for which up to 25% of LCL infections resulted in mucosal leishmaniasis. 63 Mucosal leishmaniasis is characterised by the ability of the parasite to metastasise to mucous tissues by lymphatic or haematogenous dissemination. It typically begins with nasal infl ammation and stuffi ness (ie, mild mucosal leishmaniasis), followed by ulceration of the nasal mucosa and perforation of the septum. In some cases, the lips, cheeks, soft palate, pharynx, or larynx are also involved (ie, severe mucosal leishmaniasis; fi gure 4). Mucosal leishmaniasis never heals spontaneously, is very diffi cult to treat, with secondary bacterial infections common, and is potentially fatal.
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Disease pathogenesis and immunology
The life cycle of leishmania parasites, whether in the sandfl y vector or the human host is shown in fi gure 5. The establishment of the primary leishmania infection and Sandfly takes a blood meal and regurgitates promastigotes into skin 1
Promastigotes are phagocytosed by macrophages 2
Promastigotes transform into amastigotes inside macrophages 3 Amastigotes multiply in cells (including macrophages) of various tissues 4
Amastigotes transform into promastigote stage in gut 7
Divide in gut and migrate to probiscis 8
Sandfly takes a blood meal 5
Ingestion of parasitised cell 6
Sandfly stages
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Figure 5: Life cycle of leishmania parasites
When biting their hosts, infected sandfl ies regurgitate leishmania promastigotes into the skin (1), 64 which invade or are phagocytosed by local or recruited host cells, mainly macrophages (2) . 65 Within the phagolysosomes of resident macrophages, promastigotes become amastigotes (3). Amastigotes replicate and may then infect additional macrophages, either locally or in distant tissues after dissemination (4). When blood-feeding on an infected host (5), naive sandfl ies become infected with amastigotes (6), which transform back into promastigotes in the sandfl y's gut (depending on Leishmania spp, diff erent regions of the gut will be parasitised; 7). The parasites then migrate to the sandfl y's proboscis (8), thus completing the leishmania life cycle. Adapted from the US Centers for Disease Control and Prevention.
Review development of clinical disease depend on parasite, host, and sandfl y factors; dose or route of inoculation; and the maintenance of macrophages in an inert, deactivated state. 66 Pathogenesis follows a complex set of interactions between many factors triggered by the host's innate and acquired immune responses (eg, macrophages, neutrophils, natural killer cells, dendritic cells). 67 These infl ammatory responses mediate disease expression and may result in either symptomless or subclinical infection, self-healing LCL, or chronic leishmaniasis (eg, DCL, mucosal leishmaniasis, leishmaniasis recidivans). Clinical cure ensues when macrophages become activated to a leishmanicidal state. This is mainly mediated by the T-helper cell type 1 (Th1) response, which also prevents recrudescence of latent chronic infection. The Th1 response is characterised by antigen-presenting dendritic cells, responding CD4 and CD8 T cells, and secretion of proinfl ammatory cytokines (eg, interleukin 12, interferon γ, and tumour necrosis factor α [TNFα]). 67 Downregulating cytokines (eg, interleukin 4, interleukin 10, interleukin 13, transforming growth factor β [TGFβ]) characterise the Th2 response, which deactivates macrophages and prevents excessive production of protective cytokines. 67 Although the Th2 response probably prevents extensive tissue destruction, it promotes intracellular infection.
To maintain a memory cell response dependent on continuous antigen presentation, lifelong protection against reinfection may involve live parasite persistence (eg, Leishmania subgenus Viannia DNA is detected in scars and blood of clinically cured patients) 68, 69 and repeated challenges by parasites via new bites of infected sandfl y vectors. Recurrence caused by reactivation of persistent infections or trauma may occur, 70, 71 and some patients develop a second cutaneous lesion at a diff erent site after their primary lesion has healed.
Our knowledge of the immune response to leishmania infection mainly stems from studying leishmania infection in various experimental models, 72 of which the L major murine model has been the most dominant, and has been extensively reviewed. 67, 73, 74 This response can be summarised as follows: (1) disease resolution is mediated by the cell-mediated response rather than the humoral immune response; (2) the primary activation of T-cell subsets is important for the development of Th1 and Th2 responses and the subsequent course of infection; and (3) there is strong correlation between activation of diff erent T-cell subsets and outcome of disease.
Studies of the cellular immune responses in human beings have mostly been descriptive, because of the diffi culties in defi ning the immunopathological and protective mechanisms in leishmania infections, the necessity to do longitudinal studies, and by the genetic heterogeneity of human and parasite populations. Although epidemiological data from surveys of patients seem to confi rm the Th1/Th2 dichotomy shown in experimental animal models, other studies show that the human immunological response is not exclusively explained in terms of Th1/Th2 subsets. 75 LCL patients, who present limited and ulcerated skin lesions, represent the so-called healing form of the disease. Their peripheral blood mononuclear cells (PBMCs) proliferate and produce Th1-type cytokines, including interferon γ, when stimulated with leishmanial antigens in vitro.
76-78 Their delayed-type hypersensitivity (DTH) response (as measured by the Montenegro skin test) is positive, with Montenegro skin test induration size correlated to lesion size and occasionally to lesion number. 79, 80 By contrast, patients with recurrent infections have a weaker DTH response than patients with subclinical infections, 81 as do patients with relapses when compared with those with reinfections; 70 their PBMCs produce low concentrations of interferon γ and high concentrations of interleukin 4 when stimulated with leishmanial antigens, 82 emphasising the role of a Th2-type response in chronic infections. Cytokine profi les may vary with time during the course of infection: although large concentrations of interferon γ are produced on leishmanial antigen presentation in situ (eg, as detected in lesion biopsies), 76, 77, 83 during the early phase of infection (<60 days) interferon-γ production may be downregulated by high concentrations of interleukin 10, 84 which may account for a transient period of high local parasite multiplication. There is no evidence, however, that patients with low initial interferon-γ production are at risk of developing larger lesions or parasite dissemination; in fact, they may have a better response to therapy with pentavalent antimonial drugs. 77 DCL patients display a predominantly Th2-type cytokine response, in that DCL patients have a complete anergy to leishmanial antigen, with a negative DTH response and lymphocytes non-responsive to leishmanial antigen. DCL patients have low concentrations of interferon γ and interleukin 12, but substantial serum concentrations of interleukin 4, interleukin 5, and TNFα. 85 Patients with mucosal leishmaniasis show a mixture between Th1 and Th2 cytokine responses (with high levels of interleukin 2, interleukin 4, interleukin 5, and TNFα), 76, 77, 86 which could explain non-resolution of disease, because the Th2-type response tends to dominate when both types of responses are activated. 67 Mucosal leishmaniasis patients tend to have a larger DTH response than LCL patients, with comparatively high serum concentrations of interferon γ and interleukin 2, as well as interleukin 5 and TNFα. 76, 77, 84 So far, there are no known immunological markers that may help to identify those LCL patients who are at risk of developing mucosal leishmaniasis. Indeed, studies showing diff erences in the immune response to diff erent parasite strains or species are scarce. For example, the DTH response to leishmanial antigen is greater in L braziliensisinfected patients than in L panamensis-infected patients, Review even after adjusting for time of evolution and lesion type (ie, LCL or mucosal leishmaniasis). 87 Only a few studies have reported on parasite-specifi c cytotoxic T-cell responses. 88, 89 Several reports implicate natural killer cells and CD8 T cells in interferon-γ production and immunity in human cutaneous leishmaniasis. 90, 91 By using granzyme B as a surrogate marker of leishmania-specifi c cell-mediated cytotoxicity, Bousoff ara and colleagues 92 recently showed that parasitespecifi c cytotoxic immune responses are developed by individuals living in areas of L major transmission, and play a crucial part in resistance to re-infection (Louzir H, unpublished data). Finally, the role of regulatory T cells in cutaneous leishmaniasis has only recently been investigated, with distinct subpopulations of CD4 CD25 regulatory T cells shown to stimulate TGFβ1 production by PBMCs from healthy individuals when incubated with L guyanensis parasites. 93 Regulatory T cells can also be found in skin lesions of patients with cutaneous leishmaniasis caused by L braziliensis, which produce large amounts of interleukin 10 and TGFβ1. 94 These fi ndings suggest that, like in the mouse model, 73, 74 functional regulatory T cells accumulate at sites of leishmania infection in human beings and possibly contribute to the local control of eff ector T-cell functions and thereby aff ect parasite persistence.
Parasite eff ects and factors
The contribution of the parasite to the clinical cutaneous leishmaniasis pleomorphism has been supported for years at species and intraspecies levels by several studies showing a correlation between specifi c genotypes and clinical forms (eg, L infantum zymodemes causing visceral or cutaneous disease). 95 Other studies have, however, failed to identify such correlation, 96 and underscore the complementary role of host and other factors in clinical sequelae.
Several determinants of parasite virulence have been identifi ed experimentally, all of which may help the parasite to evade the host's immune system. These can be classifi ed into three main categories: (1) invasive or evasive determinants (eg, lipophosphoglycans, leishmanolysin, or cysteine proteases), which are crucial for infection, but unable to produce pathology in the host; (2) pathoantigenic determinants (eg, histones, chaperones, or proteasomes), which lead to host immunopathology as the principal cause of clinical symptoms; and (3) protective determinants (to be identifi ed), which seem to lead to clinical cure. 97 Of note is that most virulence studies are based on a single Leishmania sp strain in well-controlled models in vitro or in vivo, which may not be applicable to human pathology. 98 Indeed, genetic diversity is a major advantage to the parasite, and it seems that Leishmania spp diff er in their approach to tackle the host immune system. 99 For example, lipophosphoglycans are a clear virulence factor in L major, but not in L mexicana, 100 and distinct L braziliensis isolates induce diff erent paces of chemokine expression patterns. 101 In this context, molecular epidemiologists should consider alternative markers to the established neutral markers (eg, isoenzymes or ribosomal DNA internally transcribed spacers) for genotyping natural populations, and focus on the polymorphism of virulence determinants. 102 The informative power of such an approach is shown by the fi nding that L peruviana (reportedly of high pathogenicity but low virulence) diff ers from L braziliensis (reportedly of low pathogenicity and high virulence) by the deletion of half the leishmanolysin genes, 103 and that leishmanolysin genes are highly polymorphic in leishmania populations, particularly in immunodominant B-cell and T-cell epitopes. 104 PCR-based assays targeting leishmanolysin and other virulence genes are becoming available for such a molecular epidemiology approach, 105, 106 but should be complemented by studies at transcriptomic and proteomic levels.
Host eff ects and factors
Susceptibility to cutaneous leishmaniasis can be greatly infl uenced by malnutrition, 107 immuno suppression (eg, HIV), 12 and host genetic background. 108 Comparative studies focusing on diff erent ethnic groups (eg, mucosal leishmaniasis caused by L braziliensis in Bolivia), 109 natives and migrants (eg, LCL caused by L major in Saudi Arabia), 110 or by familial clustering studies (eg, mucosal leishmaniasis caused by L braziliensis in Brazil), 26 have shown that human genetic components control cutaneous leishmania susceptibility and resistance. Identifi cation of candidate genes or regions involved in the genetic control of leishmaniasis has been made possible by a mouse-to-human approach, whereby susceptibility or resistance genes have been identifi ed in murine models, 111 and refi ned by the knowledge of the human immune response to leishmaniasis and genetic studies of other intramacrophage pathogens. Thus, studies in human beings indicate a role of HLA molecules in LCL and mucosal leishmaniasis, 112 and the role of TNFα in developing mucosal leishmaniasis. 113 However, a strong imbalance exists between the number of experimental analyses in mice and studies in a natural human context. In consideration of the diversity in the above-mentioned parasite approach of the host, whether host genetic determinants of leishmaniasis will be the same for diff erent Leishmania spp remains to be established.
Sandfl y vector eff ects and factors
In the past decade, it has become clear that sandfl y saliva is crucial in the establishment of infection and disease pathogenesis. 114 Sandfl y saliva is vasodilatory and enhances erythema (caused by the maxadilan peptide in Lutzomyia longipalpis); increases parasite burden, lesion size, and persistence after co-inoculation with L major, L amazonensis, and L braziliensis; and intraspecifi c variation in saliva Review components determines clinical outcome after L infantum infection. The immunological basis for these fi ndings is not fully understood, but it seems that saliva proteins can shift the adaptive immune response from a Th1 to a Th2 cell-mediated immune response (eg, by increasing the production of interleukin 4 and interleukin 6, or by inhibiting TNFα, interferon γ, interleukin 12, and nitric oxide production). Furthermore, experimental or natural pre-exposure to sandfl y saliva cancels any enhancing eff ect from subsequent co-inoculation of saliva with L major, reducing parasite load and lesion size, as well as increasing the DTH response and reducing interleukin-4 production. 115 This protective eff ect seems to be mediated by anti-saliva antibodies produced after saliva exposure. If this phenomenon exists under natural conditions, it may explain why cutaneous and mucosal leishmaniasis host susceptibility declines with age, as observed in people in cutaneous leishmaniasis-endemic areas. 
Diagnosis and treatment Diagnosis
The broad clinical spectrum of cutaneous leishmaniasis makes diagnosis of present and past cases diffi cult. Diff erential diagnosis is important because diseases of other causes but with a similar clinical spectrum to leishmaniasis (eg, leprosy, skin cancers, tuberculosis, cutaneous mycoses) are common in leishmaniasisendemic areas.
14 Parasitological diagnosis remains the gold standard in cutaneous leishmaniasis diagnosis, because of its high specifi city. It includes microscopic examination of Giemsa-stained biopsy smears or aspirates, histopathological examination of fi xed lesion biopsies, or culture of biopsy triturates or aspirates.
14 Microscopic examination is probably the most common diagnostic approach used, because more sophisticated techniques are expensive and rarely available at primary, secondary, and tertiary health-care levels in endemic areas. Culture methods are probably the most informative, allowing species identifi cation and characterisation, but require a wealth of technical expertise, and are time-consuming and expensive. The sensitivity of these techniques, however, tends to be low and can be highly variable, depending on parasite number and dispersion in biopsy samples, technical expertise, and culture media. Molecular parasitological diagnosis for cutaneous leishmaniasis was developed extensively during the past decade, and has been recently reviewed. 116 It is essentially done by PCR-based methods and is particularly useful in cases with low parasite load (eg, mucosal leishmaniasis); potentially, therapy of cutaneous leishmaniasis patients could also be monitored. Whereas reported specifi city is 100%, sensitivity is improved by 20-30% in LCL and 55-70% in mucosal leishmaniasis when compared with conventional parasitological diagnosis. Although there has been substantial eff ort in applying molecular diagnostics in the fi eld (eg, successful detection of parasite DNA in blood or tissue smears; development of rapid PCR oligochromatography), its widespread use is still hampered by the requirement of substantial laboratory infrastructure, technical expertise, and cost. 116 Until these hurdles can be overcome, molecular diagnosis will be limited to well-established reference laboratories, or travel medicine clinics.
Serological diagnosis is rarely used in cutaneous leishmaniasis diagnosis because of variable sensitivity and specifi city. 117 The Montenegro skin test is occasionally used in diagnosis of cutaneous disease (eg, in epidemiological surveys), because of its simple use and high sensitivity and specifi city; 118 however, it fails to distinguish between past and present infections.
Treatment
Although non-fatal, cutaneous leishmaniasis is treated to accelerate cure to reduce scarring, especially in cosmetic sites, and to prevent parasite dissemination (ie, mucosal leishmaniasis) or relapse. Treatment is commonly given for persistent (>6 months duration), multiple, or large lesions, and for lesions located on joints or on the face. In most leishmaniasis-endemic countries, offi cial Ministry of Health policy is to provide free treatment to all patients. This is often not feasible in practice, because drugs may be in limited supply, particularly in the mostly rural areas where the disease occurs. Thus, self-help patient associations or non-governmental organisations may facilitate diagnosis and treatment of patients (eg, Bolivia, 119 Peru, 17 and Afghanistan 6 ). Except for the immunotherapy policy in Venezuela, 120 and the pentamidine treatment policies in French Guyana and Suriname, 121, 122 WHO recommends treating cutaneous leishmaniasis with pentavalent antimonial drugs (ie, sodium stibogluconate or meglumine antimonate) at 20 mg/kg per day for 20-28 consecutive days. Barring one exception, 123 this regimen has been shown to be more effi cient than a daily dose of 10 mg/kg, 13 mg/kg, or 15 mg/kg in treating LCL. 124, 125 The main problems in treating cutaneous leishmaniasis are that clinical diagnosis is diffi cult in the absence of microscopy at the basic health-care level, and pentavalent antimonial drugs can have serious, although usually reversible, side-eff ects (eg, musculo skeletal pains, renal failure, hepatotoxicity, and cardiotoxicity), 124, 125 and are of variable effi cacy against mucosal leishmaniasis.
126 Drugs and medical attention because of the side-eff ects make treatment expensive, and reports on patients nonresponsive to the drugs either because of drug-resistant parasite strains 13 (although a recent study has questioned the defi nition of true parasite resistance) 127 or to immunosuppression (eg, caused by HIV) 12 are increasing. Moreover, the invasiveness of the standard treatment protocol (ie, a lengthy course of intramuscular or intravenous injections) means that many patients fail to complete their full course of treatment. 128 Hence, to reduce systemic toxic eff ects, economic cost, and poor Review treatment compliance, most research in the past decade has focused on the development of alternative dosage schedules, modes of delivery (ie, parenteral vs local, or topical vs oral), or treatments. 125 Recommended and alternative treatment regimens are shown in table 2, categorised by treatment modality and leishmania cause. We reviewed currently available data and conclude that for cutaneous leishmaniasis, pentavalent antimony, given parenterally or intralesionally, remains the fi rst-line treatment approach. Alternative treatment regimens include amphotericin B, especially for mucosal leishmaniasis, and pentamidine. Several studies have shown the effi cacy of miltefosine and thermotherapy, which should also be considered as alternative treatments, depending on leishmania cause and clinical manifestation. For other treatment regimens, not enough consistent data exist in our view to show their effi cacy against cutaneous leishmaniasis, and these are not recommended for use in routine clinical practice.
A few groups of studies are worth mentioning because of their potential relevance for antileishmanial treatment policy. First, several studies on patients infected with L panamensis in Colombia, 130 L braziliensis in Guatemala, 131 and L tropica in the USA, 132 have shown no substantial diff erence when reducing the treatment duration with 20 mg/kg per day pentavalent antimony from 20 days to 10 days. Extending the treatment from 28 days to 40 days does not lead to an increase in clinical cure in patients with mucosal leishmaniasis, with proportions being the same for both patient groups. 154 Thus, there seems to be room to reduce treatment time when using antimony, particularly if there is no increased risk of secondary leishmanial diseases (eg, mucosal leishmaniasis or leishmaniasis recidivans), the advantage being a reduction in systemic toxicity and treatment cost.
Second, numerous studies have shown that intralesional pentavalent antimony administration (fi gure 6) can be very eff ective in treating patients with LCL caused by L major, 134 L tropica, 128 L braziliensis, 155 or L panamensis. 156 The advantages of this approach are that a higher drug concentration targets the site of infection, reducing Review systemic toxic eff ects, improving healing time, and reducing cost (eg, in Afghanistan, the cost of successfully treating cutaneous leishmaniasis can vary substantially, depending on whether a patient is treated intralesionally or intramuscularly). 157 The drawbacks are that there is no set protocol (ie, the drug amount used is dependent on lesion number, size, and location), and treatment administration requires substantial technical expertise. 20 Third, several less toxic formulations of amphotericin B have been developed (eg, AmBisome, Amphocil, and Abelcet). These have been tested in vitro and in vivo, 158 but unlike for visceral leishmaniasis, [2] [3] [4] their cost has restricted their use in cutaneous leishmaniasis treatment to a handful of (successful) case studies. 159, 160 Fourth, several studies have shown the effi cacy of oral (eg, ketoconazole, fl uconazole, miltefosine) or topical (eg, paromomycin cream, thermotherapy) treatment regimens (table 2) . Whereas certain regimens have been pursued more vigorously and consistently (eg, miltefosine), others have been less so, probably as a result of the high costs of the branded drug (eg, ketoconazole), cream (eg, paromomycin), or hardware (eg, radiofrequency generator used in thermotherapy). However, some of these treatment alternatives may substantially reduce treatment duration and non-compliance of patients, and, hence, ultimately prove cost-eff ective.
Finally, there is increasing evidence that the treatment response of patients with cutaneous leishmaniasis depends on the infecting Leishmania spp. For example, miltefosine was shown to have high effi cacy in treating L panamensis patients in Colombia, but had a reduced Types of regimen: fi rst-line treatment regimens; alternative treatment regimens that could be used should patients fail their fi rst treatment course; and other treatment regimens that have been tested but for which comprehensive effi cacy data have yet to be accumulated. With the exception of the studies assessing treatment options for mucosal leishmaniasis (ML), we only included clinical trials that: (1) assessed monotherapies; (2) had a placebo or pentavalent antimony control group administered intramuscularly, intravenously, or intralesionally; and (3) included treatment cohorts with a minimum sample size of ten. Also, reviewed studies had to clearly state effi cacy endpoints and number of patients cured or failed according to these defi ned effi cacy endpoints. 45 with the possibility for a species-specifi c tolerance to miltefosine supported by susceptibility data in vitro. 161 Despite the numerous clinical trials that have tested diff erent treatment approaches for cutaneous leishmaniasis, comparisons between studies are problematic. First, cutaneous leishmaniasis lesions can self cure. Failure to include either negative (placebo) or positive (recommended standard treatment, such as pentavalent antimony) controls in the studies makes the interpretation of an eff ect of diff erent drugs, doses, or schedules impossible, especially if small numbers of patients are used to assess treatment response. Second, infecting parasite species and strains clearly vary in their sensitivities to drugs, and cure rates of cutaneous leishmaniasis patients with moderate or severe disease (LCL vs mucosal leishmaniasis) are very diff erent; infecting parasites should be characterised if fi nancially and logistically feasible. Healing rates also depend on host factors, such as localisation and chronicity of lesions, underlying illness or concomitant infection, and acquired resistance to leishmania infection; thus, such data should be collected. Third, studies vary in experimental protocol (eg, study design, duration of follow-up) and in particular in their defi nition of clinical cure. For example, clinical cure may be defi ned as, "when lesions have more than 80% re-epithelialised by the fi rst follow-up at 1·5 months", 53 or as, "complete re-epithelialisation of all lesions at the end of treatment and no reactivation or mucosal involvement during follow-up". 130 Standardised endpoints should be established.
Disease control Vector and reservoir control
Because the strategies available are expensive and labour intensive, and because cutaneous leishmaniasis is a nonfatal disease, prevention and control strategies have mainly focused on treatment of the human disease, rather than on the elimination of reservoirs or reduction of human-vector contact. 162 Hence, most approaches have been limited to pilot research studies and only a few have been brought up to operational scale. 163 Sandfl ies are highly susceptible to insecticides. Although they possess the necessary biochemical mechanisms, 164 reports of resistance are few. 162 Anecdotal evidence from Peruvian and Iranian malaria eradication campaigns in the 1950s suggested that residual spraying of houses is eff ective against endophilic and endophagic sandfl y vectors, which was subsequently shown in controlled studies. 162, 165 Measures involving the participation of the at-risk human population focus on personal protection from cutaneous leishmaniasis (fi gure 6), including insecticide-impregnated materials (eg, bednets, 162, 163, [165] [166] [167] [168] curtains, 167, 169 clothes, 162 or bedsheets) 165 and repellents, 162, 170 which may off er an alternative in places with poor health-service infra structure and peridomestic leishmania transmission. Several studies have shown that pyrethroid-treated bednets provide 50-65% protection against infection or disease. 162, 163, [165] [166] [167] [168] However, similar to house spraying, the long-term feasibility of insecticide-treated materials is debatable, because of logistical constraints (eg, re-impregnation of materials) and the intervention's economic cost. Opportunities for cost-eff ective scale-up of cutaneous leishmaniasis prevention and control through insecticidetreated materials are the recent development of longlasting insecticide-treated nets (ie, WHO-approved Olyset [Sumitomo Chemical, Tokyo, Japan] and PermaNet [Vestergaard Frandsen, Lausanne, Switzerland] nets, which are already extensively used in malaria control) or long-lasting insecticide formulations (ie, K-O TAB, Bayer Environmental Science, Monheim am Rhein, Germany). In forested environments (ie, in most endemic areas of South and Central America) health authorities are usually limited to treating human cutaneous leishmaniasis cases. Although prevention and control strategies (eg, environmental management, spraying of sandfl y resting sites) have been explored, 162 targeting the sandfl y vector eff ectively in these habitats is diffi cult. 
Review
We know of only one reported example of reservoir control as a cutaneous leishmaniasis prevention and control strategy, in which zoonotic LCL caused by L major was controlled by destroying burrows of the rodent LCL reservoir. 33 In endemic areas where dogs are domestic reservoirs of cutaneous leishmaniasis, 16 deltamethrinimpregnated dog collars could be an eff ective and feasible strategy, especially if these areas are sympatric for visceral leishmaniasis or Chagas disease. 171, 172 To be sustainable in the long-term, cutaneous leishmaniasis control strategies will have to be integrated into a strategy addressing other vector-borne diseases (eg, malaria or Chagas disease).
Vaccines
The rationale for vaccine development is provided by the evidence that most individuals that had leishmaniasis or symptomless infection are resistant to subsequent clinical infections. As outlined in recent reviews, [173] [174] [175] substantial eff ort has been spent in developing a leishmania vaccine, an eff ort that has so far remained fruitless. The only proven cutaneous leishmaniasis vaccine (practised for centuries) is the deliberate inoculation of virulent leishmania parasites, so-called leishmanisation. 176 However, for several basic and logistic problems (eg, diffi culties in maintaining parasite virulence, risk of unacceptable lesions in some recipients), leishmanisation is not currently recommended by WHO. Its use is restricted to a few countries (eg, Uzbekistan), notably as an evaluation method of new leishmaniasis vaccines. With the support of WHO's Research and Training in Tropical Diseases programme, several vaccines, based on killed parasites, have been developed and assessed for their immunogenicity and effi cacy in South and Central America, Sudan, and Iran. [173] [174] [175] In all these studies, the Montenegro skin test, PBMC proliferation, or interferon-γ production were used as indicators of Th1 response for the selection of naive individuals and as a correlate for protection. Although tested vaccines were safe and immunogenic (ie, in terms of leishmanin skin test conversion or increase of specifi c interferon-γ production by PBMC), signifi cant, long-lasting protection could not be shown. It seems that in leishmania vaccine studies, the specifi c DTH reaction induced by vaccination is not predictive of protection. These observations contradict the protective eff ect of leishmanin skin test reactivity in naturally infected individuals, 79, 177 and emphasise the complexity of Leishmania spp susceptibility and resistance mechanisms.
New approaches are now being investigated in the experimental leishmaniasis mouse models, with several Leishmania spp and sandfl y saliva proteins having been identifi ed as candidate vaccines. [178] [179] [180] It is hoped that the recent completion of the genome sequence for L major, 181 and soon Lu longipalpis, 182 will yield novel strategies for vaccine development that take advantage of recent progress in molecular biology, immunology, and postgenomics.
Conclusions
The leishmaniases are a complex group of diseases and although we know much more than we did a decade ago, we are no nearer to the prevention or control of this neglected disease, which mainly aff ects the world's poorest populations. 183 To do so requires professional and fi nancial commitment, focusing on key research and policy areas (panel). Over the past decade, several reviews and reports have identifi ed priorities in research and public-health policy with regard to cutaneous leishmaniasis. These have ranged from increasing eff orts in vaccine research and development of antileishmanial combination therapies to the encouragement of multidisciplinary studies to consider the tremendous diversity of natural leishmania populations in protocol design and to maximise project output. Although some of these priorities are still relevant today, we believe that others should be included to bring the fi eld signifi cantly forward.
Management of patients can be substantially improved, by developing better approaches to case detection and treatment. Better case detection and epidemiological based on poor notifi cation data and do not include social impact (disability) caused by scarring of lesions • Investigate associations between disease distribution, sociodemographic, and environmental risk factors at both small and larger levels so that rational prevention and control strategies can be developed • Support fi eld studies to investigate sandfl y ecology, because they are fundamental in developing putative prevention and control strategies
Public-health policy
• Harmonise leishmaniasis notifi cation, prevention, and control guidelines in endemic countries to allow better estimates of burden of disease • Expand use of generic sodium stibogluconate, because it has shown to be as eff ective as branded antimony for treating cutaneous leishmaniasis and at a fraction of the economic cost • Expand use of local, oral, and topical antileishmanial therapies, especially in areas where patient compliance and drug supply are problematic • Develop cost-eff ective prevention and control strategies, especially if these can be integrated into programmes to control other diseases (eg, malaria or Chagas disease)
Review surveillance are also required to better quantify the disease burden of cutaneous leishmaniasis. Several epidemiological aspects deserve further study. The relative association and contribution of environmental factors, parasite and vector species, exposure and susceptibility factors generating predisposition to disease, and distributions of infection and disease are poorly understood, and need to be elucidated for the design of any control strategy. If, for example, susceptibility factors are dominant, then comprehensive research on chemotherapy and vaccines should focus on how best to protect susceptible individuals; if exposure factors are more important, then the identifi cation of risk factors would help to guide the design of prevention strategies.
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Search strategy and selection criteria
A comprehensive literature search of medical databases (Medline and Cochrane library) and non-medical search engines was done using several keywords: "leishmaniasis", "leishmaniosis", "leishmania", "cutaneous", "mucosal", "mucocutaneous", and "diff use". We paid particular attention to articles published in the non-English literature, as these have had little exposure in previous reviews. If appropriate, we contributed our personal knowledge on the subject. Our review focused on studies undertaken or published in the past 10 years.
